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Abstract (250 words) 22 
The term double diabetes (DD) has been used to refer to individuals with type 1 23 
diabetes who are overweight, have a family history of type 2 diabetes and/or clinical 24 
features of insulin resistance. Several pieces of evidence indicate that individuals who 25 
display features of DD are at higher risk of developing future diabetes complications, 26 
independent of average glucose control, measured as glycated haemoglobin (HbA1c). 27 
Given the increased prevalence of individuals with features of DD, pragmatic criteria 28 
are urgently required to identify and stratify this group, which will help with subsequent 29 
implementation of more effective personalised interventions. 30 
In this review, we discuss the potential criteria for the clinical identification of 31 
individuals with DD, highlighting the strengths and weaknesses of each definition. We 32 
also cover potential mechanisms of DD and how these contribute to increased risk of 33 
diabetes complications. Special emphasis is placed on the role of estimated glucose 34 
disposal rate (eGDR) in the diagnosis of DD, which can be easily incorporated into 35 
clinical practice and is predictive of adverse clinical outcome. In addition to the 36 
identification of individuals with DD, eGDR has the potential utility to monitor response 37 
to different interventions.  38 
Type 1 diabetes is a more heterogeneous condition than initially envisaged and 39 
those with features of DD represent a subgroup at higher risk of complications. 40 
Pragmatic criteria for the diagnosis of individuals with DD will help with risk 41 
stratification, allowing a more personalised and targeted management strategy to 42 
improve outcome and quality of life in this population. 43 
  44 
  45 
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Introduction  46 
Type 2 diabetes (T2D), usually due to insulin resistance and gradually 47 
progressive pancreatic く-cell failure1, is a common condition and characterised by high 48 
heterogeneity. In contrast, Type 1 diabetes (T1D), insulin deficiency, has been 49 
regarded as a condition with a largely uniform phenotype However, the development 50 
of insulin resistance in individuals with T1D has led to the emergence of a distinct 51 
phenotype of mixed T1D and T2D, or double diabetes. Therefore, classification of 52 
diabetes is not that simple and indeed recent work has stratified these individuals into 53 
different subgroups. It was suggested that this will help predict disease progression 54 
and predisposition to complications, offering the possibility of future individualised and 55 
tailored therapies2,3.  56 
Despite first using the term ‘double diabetes’ (DD) over a quarter century ago, 57 
there is still a lack of clear criteria to define this group of individuals. The earliest 58 
description of DD dates back to 19914, when Teupe and Bergis demonstrated that 59 
T1D individuals who had at least one relative with T2D had worse glycaemic control 60 
with increased insulin requirements, and tended to have a higher body weight 61 
compared to those without a family history of T2D. The authors, therefore, proposed 62 
a subtype of T1D with family history of T2D as having DD. A number of case reports 63 
followed describing individuals with DD using similar criteria; the case by Libman and 64 
Becker was particularly interesting by demonstrating that features of DD can manifest 65 
as early as 5 years of age with full traits of insulin resistance and the metabolic 66 
syndrome (MS) evident by the age of 14 years5. However, no clear recommendations 67 
were made for identifying these individuals or implementing alternative and targeted 68 
management strategies.   69 
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 In this review, we provide an update on DD and attempt to address three main 70 
questions: 71 
1) What is the best and most pragmatic measure to identify individuals with DD?  72 
2) Is there a difference in the rate or severity of diabetes complications in DD, 73 
and if this is the case, what are the mechanisms involved?   74 
3) To what extent do patients with DD require different management strategies? 75 
 76 
Definition of double diabetes 77 
Criteria for the definition of DD to date have relied on the presence of clinical features 78 
of insulin resistance, as summarised in two comprehensive review articles (Table 1) 79 
6,7. While these proposals have raised awareness of the DD population, criteria used 80 
to make a diagnosis have been difficult to incorporate into daily clinical practice. In 81 
order to provide an accurate definition of DD, we need to explore the strengths and 82 
weaknesses of the existing criteria, which can be largely divided into three groups: 83 
family history, obesity/MS, and insulin resistance. 84 
1. Family history  85 
There is a genetic predisposition in T1D as concordance rate in monozygotic 86 
twins is 5-fold higher than dizygotic twins 8,9. However, almost 90% of patients report 87 
no family history of T1D and therefore the genetic influence is modest. In contrast, the 88 
role of genetic factors are far stronger in T2D with 3- and 6-fold increased risk in 89 
offspring if one or both parents have type 2 diabetes, respectively 10. At least 88 genetic 90 
loci for T2D have been discovered by linkage and genome-wide association and 91 
sequencing (GWAS) studies, where identified loci have been implicated in both 92 
pancreatic く-cell function and insulin resistance/MS 11,12. One particular variant of FTO 93 
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(fat mass– and obesity-associated) gene is linked to insulin resistance, increased fat 94 
mass and preferential visceral fat distribution, thus increasing T2D risk 13. Moreover, 95 
several common gene variants are also related to insulin resistance in T2D, 96 
independently of obesity14.  97 
In DD, it is possible that individuals with T1D have a genetic predisposition to 98 
insulin resistance and T2D, particularly in those with concomitant family history of T2D. 99 
Healthy subjects with family history of T2D exhibit a greater degree of insulin 100 
resistance and are prone to have higher BMI, and body fat composition, even prior to 101 
the development beta-cell failure 15. A similar mechanism may be operating in double 102 
diabetes but not necessarily in the same order; insulin resistance may develop later in 103 
the course of T1D, although it can be present at diagnosis and may even contribute to 104 
an earlier presentation of T1D. This explains the first description of Teupe and Bergis 105 
in 70 T1D patients with a family history of T2D, of a total group of 448 individuals 4. 106 
Those with DD had higher BMI, insulin dose and glycated haemoglobin A1c (HbA1c) 107 
compared with the rest of the group. Supported by a larger study of 1,860 T1D 108 
individuals aged less than 35 years (from the Finnish Diabetic Nephropathy study), it 109 
showed that 620 individuals had a family history of T2D, who again had higher BMI, 110 
insulin dose, HbA1c and triglyceride levels.  111 
Data from 1,168 T1D patients from the Diabetes Control and Complication 112 
study (DCCT) has shown that a family history of T2D was related to greater central 113 
weight gain, insulin dose and triglyceride levels in the intensive arm of the study 16. 114 
Moreover, family history of T2D was also related to elevated LDL cholesterol and 115 
apolipoprotein B levels in both study arms. The greater weight gain in the intensive 116 
arm suggests that intensive insulin therapy to optimise glycaemia further increases the 117 
risk of developing DD in susceptible individuals.  118 
6 
 
Despite the increase in vascular risk factors in T1D with a family history of T2D, 119 
the association with diabetes complications is not always clear. A cross-sectional 120 
study of 3,162 T1D individuals, aged 15-60 years from the EURODIAB IDDM 121 
Complications Study, only showed an association between a family history of T2D and 122 
albuminuria in female subjects 17. Similarly, an observational study in 658 T1D patients 123 
failed to demonstrate causal relationship between a family history of T2D and coronary 124 
artery disease after adjustment for confounders 18. However, it can be disputed that 125 
the number of individuals studied is limited and the period of follow up is relatively 126 
short to make concrete conclusions.   127 
Taken together, a family history of T2D is a risk for developing poorer metabolic 128 
traits and obesity in T1D, yet it does not appear to be a strong independent predictor 129 
of diabetes-related complications. However, studies have been conducted on 130 
relatively small numbers of younger individuals and silent vascular events were not 131 
ruled out, which have been shown to affect up to a fifth of asymptomatic T2D 132 
individuals 19, and this may explain the negative findings. Further adequately powered 133 
longer-term studies are required to understand the role of a family history of T2D in 134 
predisposing to complications in individuals with T1D. 135 
  136 
2. Excessive weight gain/obesity and metabolic syndrome (MS) 137 
Insulin is an anabolic hormone, so intensification of therapy is likely to lead to 138 
weight gain. While this is an acceptable compromise in those with poor glycaemic 139 
control, continued administration of insulin subcutaneously can lead to peripheral 140 
resistance to the action of this hormone20,21, consequently increasing DD risk. The 141 
secondary analysis of the whole DCCT study population showed that T1D individuals 142 
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whose weight gain stratified into the fourth quartile (excessive gainers) had higher 143 
insulin dose, blood pressure and non-HDL cholesterol 22. Moreover, individuals whose 144 
BMI increased over 4.39 kg/m2 during DCCT study period, had greater intima-media 145 
thickness and displayed a trend toward greater coronary artery calcium scores 23, 146 
providing strong evidence for vascular pathology in this group. Also, excessive gainers 147 
displayed tendency towards higher CV events after a mean follow-up of 26 years 24.  148 
We should, nevertheless, be careful when interpreting weight data, as initial 149 
moderate weight gain following diagnosis of T1D correlates with improved HbA1c and 150 
reduction in mortality. However, excessive weight gain, reaching a BMI >30 kg/m2, has 151 
repeatedly shown an association with increased mortality 25,26.  152 
Therefore, while weight gain should not be used as the sole identifier for DD, 153 
excessive weight gain, particularly in those with BMI ≥30 kg/m2, may provide a simple 154 
clinical marker to identify DD and risk of future adverse vascular outcome.  155 
The presence of MS has been proposed as a more comprehensive marker for 156 
the identification of DD. MS integrates central obesity and other traditional CV risk 157 
factors including hypertension, hypertriglyceridaemia and decreased levels of high 158 
density lipoprotein (HDL) cholesterol. The EURODIAB Prospective Complications 159 
Study (PCS), observed 3,250 T1D patients for 7 years from 16 European countries 160 
and documented that some components of the MS were associated with increased 161 
CV and all-cause mortality 27.  162 
The relationship between MS and diabetes-related complications among adults 163 
with T1D has been extensively reviewed by Gingras et al. 28, and the authors 164 
concluded that the presence of MS is associated with increased risk of both micro- 165 
and macrovascular disease.  166 
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The association of MS with future complications can depend on the type of 167 
definition used for MS with some studies, albeit not all, suggesting that WHO definition 168 
of MS is the best predictor of future complications 29,30. However, it is not practical in 169 
daily clinical practice to use a binary variable like MS to assess the risk of future 170 
complications, particularly in the presence of various definitions. Also, the effects of 171 
managing components of MS will not be apparent until an individual drops into the 172 
non-MS range, which may be a challenge in some, making patients frustrated and 173 
potentially disengaged. Therefore, MS has too many flaws to be a reliable and 174 
practical marker of DD. 175 
 176 
3. Insulin resistance and estimated glucose disposal rate (eGDR) 177 
Insulin resistance is associated with asymptomatic atherosclerosis and 178 
coronary artery disease in individuals without diabetes 31,32. A meta-analysis of 65 179 
studies, which included 516,325 adults without diabetes, has shown that insulin 180 
resistance, measured by HOMA-IR, is a good predictor of CV disease 33. In line with 181 
these findings, insulin resistance in T1D has been associated with increased risk of 182 
cardiovascular disease 34. Furthermore, the CACTI study demonstrated that insulin 183 
resistance, measured by clamp techniques, predicted the presence of coronary artery 184 
calcification in T1D 35.  185 
The gold standard method to measure insulin resistance is the euglycaemic-186 
hyperinsulinemic clamp 36. However, due to the invasive and time-consuming nature 187 
of the procedure, it is not suitable for daily clinical practice. Estimated glucose disposal 188 
rate (eGDR) has been proposed as an alternative method to measure insulin 189 
resistance that is easy to apply in clinical settings. The eGDR score was originally 190 
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developed and validated by the euglycaemic-hyperinsulinemic clamp in a subset of 24 191 
T1D patients from the Pittsburgh EDC study 37. William and colleagues initially 192 
calculated eGDR using clinical factors including waist-hip ratio (WHR), presence of 193 
hypertension and HbA1c. However, the authors also stated that replacing WHR with 194 
either BMI or waist circumferences (WC) provided a comparable association with 195 
insulin resistance 37-39. All formulae for eGDR calculation are displayed in Box 1. 196 
Box 1. Formulae for eGDR calculation 197 
eGDRWHR = 24.31 – (12.22 x WHR) – (3.29 x HTN) – (0.57 x HbA1c) WHR = waist-hip ratio 
WC = waist circumference, cm 
BMI = body-mass index, kg/m2 
HTN = hypertension, 1=yes, 0=no 
HbA1c = glycated haemoglobin A1c, % 
eGDRWC = 21.16 – (0.09 x WC) – (3.41 x HTN) – (0.55 x HbA1c) 
eGDRBMI = 19.02 – (0.22 x BMI) – (3.26 x HTN) – (0.61 x HbA1c) 
 198 
Similar to MS, eGDR incorporates weight and blood pressure, however, it is a 199 
continuous variable allowing to monitor the effectiveness of a particular therapy, 200 
making it attractive for clinical use. This is particularly important as a decrease in 201 
eGDR is associated with increased risk of nephropathy 40, peripheral vascular disease 202 
41, coronary artery disease 42,43 and death 43 with lower values conferring greater risk. 203 
The result from DCCT study also supports the relationship between low eGDR and 204 
increased risk of both micro- and macrovascular complications 44, and shows 205 
superiority at predicting complications compared with the use of MS to define DD.  206 
While eGDR appears to be a promising marker to identify DD, the cut off value 207 
requires careful consideration. Nyström et al. performed a nationwide cohort study on 208 
17,050 T1D individuals, using data from healthcare registers in Sweden. Patients were 209 
categorized into 4 eGDR groups: <4, 4 to 5.99, 6 to 7.99, and ≥8. Clinical outcomes, 210 
including CV events and death, were collected using national registry data, over a 211 
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median follow-up of 7.1 years. An eGDR <8 was associated with increased CV risk or 212 
death compared to those with eGDR >8. The risk further increased with lower eGDR 213 
values (Fig. 1) 39. Interestingly, survival rate of individuals with eGDR >8 was identical 214 
to a matched reference population. Hence, the eGDR value of <8 is convincingly 215 
suitable to identify those with DD among individuals with T1D, with higher risk incurred 216 
in those with progressively lower eGDR. 217 
 218 
Prevalence of double diabetes according to each definition  219 
Using obesity (BMI>30 kg/m2) as a measurement, the prevalence of DD amongst 220 
T1D can reach 30%, particularly as the prevalence of obesity has been increasing in 221 
the T1D population (Fig. 2) 45.  The prevalence of obesity in the DCCT/EDIC study has 222 
shown an increase from 2% at baseline (1983-1989) to 28% at 12 years of follow-up 223 
46. This may be an easy marker to use but it is likely to miss significant number of 224 
individuals with DD and therefore more accurate measures are needed. 225 
 When MS is applied for identification of DD, the prevalence is dependent on 226 
study period, population analysed, and MS definition used (Fig. 3). A range of 30-45% 227 
of T1D individuals have MS and therefore up to half the patients will have DD using 228 
this criterion. However, given the binary nature of MS definition, its only possible role 229 
in clinical management is identification of individuals at risk and it is not a useful marker 230 
to assess response to a particular management strategy. 231 
In the study by Nyström et al 39, the prevalence of DD in T1D at the beginning of 232 
the study was 51%, when applying eGDR<8 as a proposed diagnostic criterion. The 233 
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increased risk of complications with lower eGDR, makes this a suitable marker to 234 
assess response to a particular intervention, in contrast to MS. 235 
The increasing trend of DD is consistent across all measurements. Therefore, 236 
unless acted upon, DD will possibly become the predominant phenotype in T1D in 237 
next few decades.   238 
 239 
Pathogenesis of double diabetes  240 
If we accept that T1D individuals who are overweight are likely to form the core 241 
group of DD, then the pathogenic mechanisms are related to genetic predisposition 242 
and environmental factors. The latter factors can interact with T1D duration making 243 
DD a time-dependent condition. Even those with initial good insulin sensitivity and no 244 
genetic predisposition may transition to DD secondary to unhealthy lifestyle that leads 245 
to weight gain 47. While genetic predisposition is non-modifiable, environmental factors 246 
can be controlled thus limiting the prevalence of DD. Exposure to obesogenic 247 
environments affect the rates of overweight and obesity, particularly among children. 248 
Almost 32% and 16% of children with poor physical activity and unhealthy nutritional 249 
environment are overweight and obese, whereby 24% and 8% of those living in 250 
healthier environments are overweight and obese, respectively 48. However, the 251 
percentage of younger T1D individuals with a weight problem is higher than those 252 
without diabetes 49,50, indicating the presence of additional mechanisms. For example, 253 
repeated hypoglycaemia or even the fear of hypoglycaemia results in maladaptive 254 
eating habits that favour the development of obesity 51. Peripheral insulin resistance 255 
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precipitated by subcutaneous insulin administration rather than the physiological portal 256 
vein delivery, is another additional factor for the development of DD 21,34. 257 
Therefore, DD in T1D develops secondary to a combination of lifestyle 258 
behaviour, akin to individuals without diabetes, and, diabetes-specific mechanisms 259 
related to hypoglycaemia and the non-physiological administration of insulin 260 
subcutaneously.  261 
Double diabetes, glycaemic control and complications  262 
The DCCT and the extended observational EDIC studies have clearly shown that 263 
improving glycaemia, measured as a reduction in HbA1c, decreases microvascular 264 
complications and long term macrovascular disease 52,53. However, it became 265 
apparent that there was a great heterogeneity in the rate of complications, indicating 266 
that factors other than HbA1c also had a role.  267 
Merger and colleagues conducted a cross-sectional study to measure the 268 
prevalence of comorbidities in DD by analysing data in the DPV [Diabetes-Patienten 269 
Verlaufsdokumentation] registry from 392 specialized centres in Germany and Austria 270 
54. DD was defined as individuals with T1D and MS using the Third National 271 
Cholesterol Education Program Adult Treatment Panel (NCEP/ATPIII) criteria. Of a 272 
total of 31,119 T1D individuals, 7,926 had DD (25.5%), a group that displayed 273 
markedly higher micro- and macrovascular complications, even after adjustments for 274 
age, sex and diabetes duration. In a subgroup analysis of individuals with well-275 
controlled glycaemia (HbA1c <7% or 53mmol/mol), 1892 of 9203 had DD (20.6%), 276 
and showed reduced risk of complications compared to those with inadequate glucose 277 
control. However, this group still had up to 3.5 times higher rate of complications 278 
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compared with T1D patients without MS having identical HbA1c. More worryingly, the 279 
rate of complications in the well-controlled DD subgroup was higher than all T1D 280 
without MS regardless of glycaemic control (Fig. 4).  281 
In addition to increased rate of complications, mortality is also increased in 282 
individuals with DD. The hazard ratio (HR) for diabetes-related mortality from 283 
FinnDiane study was significantly higher in DD (defined as presence of MS by WHO 284 
criteria), compared to T1D without MS (adjusted HR 2.52 [95%CI: 1.53-4.16]) 29. All-285 
cause mortality in DD defined by eGDR<8 was increased 1.6-fold compared to those 286 
with eGDR >8  39.   287 
 288 
Potential mechanisms for increased complications in 289 
double diabetes 290 
A key component of DD that may increase complication rate is insulin resistance 291 
and the need for relatively larger dose of subcutaneous insulin. While HbA1c on its 292 
own does not explain the increased rate of complications in DD, other glycaemic 293 
markers such as glucose variability (GV) and/or hypoglycaemia may have a role. 294 
Alterations in traditional CV risk factors such as dyslipidaemia and hypertension are 295 
likely to play a role in increased rate of complications. The potential mechanisms for 296 
increased complications in DD are illustrated in Fig. 5. 297 
  298 
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The role of glycaemia  299 
The observational study by Merger and colleagues 54 suggests that individuals 300 
with DD who are generally more obese than those with T1D, tend to have higher 301 
HbA1c, which may, at least in part, be responsible for the increased risk of 302 
complications in DD. It should be noted that HbA1c measures average glucose levels 303 
and does not address GV or hypoglycaemia, both of which appear to be associated 304 
with adverse vascular outcome 55,56. In particular, higher insulin doses, commonly 305 
used in DD, may lead to increased risk of hypoglycaemia 57, which in turn enhances 306 
the inflammatory/thrombotic milieu thus contributing to vascular pathology 58. 307 
Moreover, the potential for larger fluctuations in glucose levels in this population may 308 
implicate GV in the increased risk of complications. However, these are merely 309 
hypotheses at present and studies are required to establish whether individuals with 310 
DD experience more hypoglycaemic events and/or higher GV, particularly in those 311 
with well controlled HbA1c. If a difference is detected, longitudinal studies are 312 
warranted to understand the relationship between these glycaemic markers and 313 
vascular complications in DD.  314 
 315 
The role of Insulin resistance 316 
Insulin resistance is associated with an enhanced inflammatory environment due 317 
to the release of cytokines by adipose tissue macrophages 59 or inflammatory proteins 318 
such as complement by adipocytes 60. This in turn enhances insulin resistance by 319 
interfering with insulin-mediated phosphinositide-3 kinase (PI3K) pathway 61,62, 320 
creating a vicious cycle. Interestingly, blocking inflammatory cytokines with the use of 321 
interleukin-1 antagonist can improve insulin sensitivity in insulin resistant patients with 322 
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T1D 63. Moreover, systemic cytokines leakage into the circulation contributes to low 323 
grade generalized inflammatory milieu, which in turn promotes endothelial 324 
dysfunction, the earliest  abnormality in the atherosclerotic process 64. 325 
Insulin resistance also increases lipolysis leading to non-esterified free fatty acid 326 
flux into the systemic circulation, where triglyceride deposition in muscle and liver 327 
tissues augments insulin resistance 65. Insulin resistance also leads to hyperglycaemia 328 
through unsuppressed hepatic gluconeogenesis and decreased muscular glucose 329 
uptake 66,67, thus resulting in higher insulin requirements. Insulin resistance contributes 330 
to an increase in blood pressure by diminishing the vasodilatation efficiency and 331 
promoting smooth muscle growth. Moreover, insulin resistance impairs PI3K-332 
dependent signalling pathway while keeping the mitogen-activated protein kinase 333 
(MAPK)-dependent pathway intact 68, resulting in imbalance between the two 334 
pathways. Compensatory hyperinsulinemia, therefore, increases production of the 335 
vasoconstrictor endothelin-1 69, which opposes vasodilator action of nitric oxide 70, 336 
through the overstimulation of the unaffected MAPK pathway 71. The overstimulation 337 
of MAPK pathway additionally activates vascular smooth muscle cell migration and 338 
proliferation 72, leading to vascular wall thickening and increased peripheral vascular 339 
resistance.  340 
Apart from insulin-signalling pathways, hyperinsulinemia results in sodium 341 
retention 73-75 through a direct anti-natriuretic effect and by upregulation of the renin-342 
angiotensin-aldosterone system 76.  343 
Other than the inflammatory environment, insulin resistance predisposes to 344 
hypofibrinolysis leading to a thrombotic environment through altered levels and/or 345 
activity of coagulation factors such as fibrinogen 77,78, plasminogen activator inhibitor-346 
1 79,80 and the inflammatory thrombotic protein complement C3 81,82.  347 
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Conclusions and future directions  348 
Evidence to date indicates that individuals with features of DD have increased 349 
risk of complications yet the clinical management of this group remains similar to 350 
others with T1D. A difficulty is the absence of reliable criteria to identify individuals with 351 
DD. Relying on a family history of T2D is inadequate while the presence of the MS is 352 
problematic given the different definitions and the difficulty in incorporating into routine 353 
clinical practice. This leaves eGDR as a credible measure of DD, which is easy to 354 
adapt clinically and has the advantage of offering a numerical value that can be used 355 
to monitor response to a particular intervention, similarly to HbA1c.  356 
We need to better understand the mechanisms leading to DD and the pathways 357 
implicated in increased risk of complications in this group. This includes the effects of 358 
different glycaemic markers such as hypoglycaemia and GV, made possible with 359 
modern glucose monitoring strategies that rely on continuous glucose values rather 360 
than sporadic capillary glucose measurements. The contribution of genetic and 361 
environmental factors to the development of DD requires further research, including 362 
the role of different insulin preparations and mode of administration. For example, it is 363 
not entirely clear whether insulin pump-treated patients have different rates of DD 364 
compared with those on multiple daily injection. 365 
The most challenging aspect, however, is clarifying the best treatment strategy 366 
in individuals with DD, a group in itself with varying degree of risk. It is possible that 367 
routine use of eGDR will allow risk stratification, potentially using this marker as an 368 
adjunct to HbA1c when assessing individuals with T1D. Naturally, lifestyle changes 369 
should be advocated in individuals with DD, including healthy diet and regular 370 
exercise. However, more sophisticated diets may be required for effective weight loss 371 
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and possibly adjunctive therapy with agents that promote an increase in eGDR. Work 372 
is also needed to elucidate whether more aggressive vascular protective strategies 373 
are required, and at an early age, in the form of blood pressure lowering anti-374 
hyperlipidaemic and anti-thrombotic agents, which will help to reduce morbidity and 375 
improve quality of life in these patients.   376 
  377 
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List of Abbreviations 378 
 379 
CV cardiovascular 
DCCT the Diabetes Control and Complication study 
DD double diabetes 
EDIC the Epidemiology of Diabetes Interventions and Complications 
study 
eGDR estimated glucose disposal rate 
FinnDiane the Finnish Diabetic Nephropathy study 
GV glucose variability 
MAPK Mitogen-activated protein kinase 
MS metabolic syndrome 
PAI-1 plasminogen activator inhibitor-1 
PI3K insulin-mediated phosphinositide-3 kinase 
T1D type 1 diabetes 
T2D type 2 diabetes 
WC waist circumferences 
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Fig. 1. Estimated glucose disposal rate (eGDR) and mortality in type 1 diabetes (T1D). All-cause 
mortality was related to eGDR, calculated using waist circumference, in 17,050 individuals with 
T1D diabetes. Data were adapted from 39. 
Fig. 2. Temporal patterns of overweight and obesity in type 1 diabetes. Data were modified from 
45. 
Fig. 3. Prevalence of metabolic syndrome (MS) in type 1 diabetes. The role of different MS 
definitions in predicting double diabetes is shown. of the MS are reviewed. Data were obtained 
from references 29,30,39,43,44,83-86. 
Fig. 4. Prevalence of diabetes complications in individuals with type 1 diabetes (T1D) and 
metabolic syndrome (MS). Complication rates (a, b) and risk ratios (c, d) of diabetes 
complications is shown in the presence and absence of MS in individuals withT1D. (CHD, 
coronary heart disease; MI, myocardial infarction; PAD, peripheral arterial disease; DR, diabetic 
retinopathy; PDR, proliferative retinopathy; ALB, albuminuria). Data were modified from 54. 
Fig. 5 Overview of the mechanisms for increased risk of complications in double diabetes. Insulin 
resistance and obesity create a low-grade inflammatory milieu which aggravates insulin 
resistance. This, in turn, leads to hyperglycemia by decreasing glucose uptake in peripheral 
tissue and increasing hepatic gluconeogenesis. Insulin resistance also causes atherogenic low-
density lipoprotein (LDL) cholesterol oxidation and hypertension by various mechanisms. 
Hyperglycaemia, atherogenic dyslipidaemia and hypertension promote endothelial dysfunction 
and atherosclerotic plaque formation. Insulin resistance and inflammation sequentially promote 
hypofibrinolysis leading to prothrombotic clot formation and vascular occlusion ( IL-6, interleukin 
6; TNF-g, tumor necrosis factor g; PAI-1, plasminogen activator inhibitor 1; C3, complement C3; 
FFA, free fatty acid; sdLDL, small-dense LDL; oxLDL, oxidized LDL; NO, nitric oxide; ET-1, 
endothelin-1; PKC, protein kinase pathway C; AGEs, advanced glycation end products; MAPK, 
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